210 related articles for article (PubMed ID: 36653361)
21. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy.
Ku B; Eisenbarth D; Baek S; Jeong TK; Kang JG; Hwang D; Noh MG; Choi C; Choi S; Seol T; Kim H; Kim YH; Woo SM; Kong SY; Lim DS
Cell Rep Med; 2024 Mar; 5(3):101461. PubMed ID: 38460517
[TBL] [Abstract][Full Text] [Related]
22. Metabolism and epigenetics of pancreatic cancer stem cells.
Perusina Lanfranca M; Thompson JK; Bednar F; Halbrook C; Lyssiotis C; Levi B; Frankel TL
Semin Cancer Biol; 2019 Aug; 57():19-26. PubMed ID: 30273655
[TBL] [Abstract][Full Text] [Related]
23. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic control of pancreatic cancer metastasis.
Krauß L; Schneider C; Hessmann E; Saur D; Schneider G
Cancer Metastasis Rev; 2023 Dec; 42(4):1113-1131. PubMed ID: 37659057
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
[TBL] [Abstract][Full Text] [Related]
26. ABCC3 is a novel target for the treatment of pancreatic cancer.
Adamska A; Ferro R; Lattanzio R; Capone E; Domenichini A; Damiani V; Chiorino G; Akkaya BG; Linton KJ; De Laurenzi V; Sala G; Falasca M
Adv Biol Regul; 2019 Aug; 73():100634. PubMed ID: 31053501
[TBL] [Abstract][Full Text] [Related]
27. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
28. Metabolism addiction in pancreatic cancer.
Blum R; Kloog Y
Cell Death Dis; 2014 Feb; 5(2):e1065. PubMed ID: 24556680
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
31. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
[TBL] [Abstract][Full Text] [Related]
32. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Hu T; Shukla SK; Vernucci E; He C; Wang D; King RJ; Jha K; Siddhanta K; Mullen NJ; Attri KS; Murthy D; Chaika NV; Thakur R; Mulder SE; Pacheco CG; Fu X; High RR; Yu F; Lazenby A; Steegborn C; Lan P; Mehla K; Rotili D; Chaudhary S; Valente S; Tafani M; Mai A; Auwerx J; Verdin E; Tuveson D; Singh PK
Gastroenterology; 2021 Nov; 161(5):1584-1600. PubMed ID: 34245764
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
34. SWI/SNF component
Wang SC; Nassour I; Xiao S; Zhang S; Luo X; Lee J; Li L; Sun X; Nguyen LH; Chuang JC; Peng L; Daigle S; Shen J; Zhu H
Gut; 2019 Jul; 68(7):1259-1270. PubMed ID: 30315093
[TBL] [Abstract][Full Text] [Related]
35. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Cioffi M; Trabulo SM; Sanchez-Ripoll Y; Miranda-Lorenzo I; Lonardo E; Dorado J; Reis Vieira C; Ramirez JC; Hidalgo M; Aicher A; Hahn S; Sainz B; Heeschen C
Gut; 2015 Dec; 64(12):1936-48. PubMed ID: 25887381
[TBL] [Abstract][Full Text] [Related]
36. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Ruess DA; Görgülü K; Wörmann SM; Algül H
Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
[TBL] [Abstract][Full Text] [Related]
38. Genomic analyses identify molecular subtypes of pancreatic cancer.
Bailey P; Chang DK; Nones K; Johns AL; Patch AM; Gingras MC; Miller DK; Christ AN; Bruxner TJ; Quinn MC; Nourse C; Murtaugh LC; Harliwong I; Idrisoglu S; Manning S; Nourbakhsh E; Wani S; Fink L; Holmes O; Chin V; Anderson MJ; Kazakoff S; Leonard C; Newell F; Waddell N; Wood S; Xu Q; Wilson PJ; Cloonan N; Kassahn KS; Taylor D; Quek K; Robertson A; Pantano L; Mincarelli L; Sanchez LN; Evers L; Wu J; Pinese M; Cowley MJ; Jones MD; Colvin EK; Nagrial AM; Humphrey ES; Chantrill LA; Mawson A; Humphris J; Chou A; Pajic M; Scarlett CJ; Pinho AV; Giry-Laterriere M; Rooman I; Samra JS; Kench JG; Lovell JA; Merrett ND; Toon CW; Epari K; Nguyen NQ; Barbour A; Zeps N; Moran-Jones K; Jamieson NB; Graham JS; Duthie F; Oien K; Hair J; Grützmann R; Maitra A; Iacobuzio-Donahue CA; Wolfgang CL; Morgan RA; Lawlor RT; Corbo V; Bassi C; Rusev B; Capelli P; Salvia R; Tortora G; Mukhopadhyay D; Petersen GM; ; Munzy DM; Fisher WE; Karim SA; Eshleman JR; Hruban RH; Pilarsky C; Morton JP; Sansom OJ; Scarpa A; Musgrove EA; Bailey UM; Hofmann O; Sutherland RL; Wheeler DA; Gill AJ; Gibbs RA; Pearson JV; Waddell N; Biankin AV; Grimmond SM
Nature; 2016 Mar; 531(7592):47-52. PubMed ID: 26909576
[TBL] [Abstract][Full Text] [Related]
39. ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.
Wang W; Friedland SC; Guo B; O'Dell MR; Alexander WB; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Myers JR; Ashton JM; Dunne RF; Steiner LA; Hezel AF
Gut; 2019 Jul; 68(7):1245-1258. PubMed ID: 30228219
[TBL] [Abstract][Full Text] [Related]
40. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]